4DMedical Shares Jump 34% to New ATH – What Happened?

4DMedical shares (ASX: 4DX) had a huge day in the markets today, soaring to an all-time high after announcing that the world’s top-ranked hospital has adopted its flagship lung scanning technology for clinical use.

The 4DMedical share price jumped 34.56%, closing at A$6.23 after touching an intraday high of A$6.47. The dramatic surge came on heavy volume, marking one of the strongest single-day gains for the respiratory imaging specialist since its listing. The stock has now added 1630% over the past 12 months, marking 4DX as a leader on the ASX 200.

Smashing through the A$5.00 psychological barrier on strong momentum is another bullish sign for technical traders. The move suggests markets are rapidly repricing the commercial potential of the company’s CT:VQ technology following validation from one of healthcare’s most prestigious institutions.

Mayo Clinic Deployment Signals Commercial Inflection

The catalyst for today’s surge was 4DMedical’s announcement that Mayo Clinic has deployed CT:VQ under a commercial agreement, marking a significant milestone for the company’s U.S. expansion strategy. CT:VQ is a software-based lung imaging solution that generates ventilation and perfusion maps from standard chest CT scans, eliminating the need for nuclear medicine tracers traditionally used in lung function assessment.

Mayo Clinic, which consistently ranks as the number one hospital in the United States according to U.S. News & World Report, joins a rapidly growing roster of elite academic medical centres adopting the technology. The deployment follows similar commercial agreements with Stanford University, Cleveland Clinic, University of Miami, and UC San Diego, all secured within approximately four months of CT:VQ receiving FDA 510(k) clearance in late 2024.

The company’s managing director and CEO, Andreas Fouras, framed the Mayo deployment as a watershed moment for market acceptance. “Mayo’s deployment is uniquely significant,” Fouras stated in the announcement. “When the world’s number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.”

Financial details of the Mayo Clinic agreement were not disclosed, consistent with 4DMedical’s approach to other institutional contracts. However, the Stanford deal, announced earlier, provides a template for potential scale, with that agreement covering analysis of up to approximately 20,000 scans annually. CT:VQ operates on a software-as-a-service model with per-scan fees, creating recurring revenue streams as adoption expands within each hospital system.

Regulatory and Reimbursement Foundation in Place

The rapid accumulation of top-tier hospital contracts reflects the regulatory and reimbursement groundwork 4DMedical has established over the past year. CT:VQ secured FDA 510(k) clearance in 2024, followed by confirmation of U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement under a Category III CPT code valued at approximately US$650.50 per scan, in addition to standard CT imaging reimbursement.

The company has since expanded its regulatory footprint with Canadian approval, enabling distribution across North America through its partnership with Philips Healthcare. The Philips reseller agreement provides 4DMedical with access to government healthcare systems, including the U.S. Department of Veterans Affairs, and leverages Philips’ established sales infrastructure across the region.

4DMedical’s financial position has been strengthened through capital raises totalling approximately A$150 million in recent quarters, providing runway to accelerate commercial rollout and fund expansion of its sales and clinical education teams. The company’s cash balance exceeds A$150 million, reducing near-term funding risk as it pursues profitability.

Recent quarterly results have shown modest revenue growth relative to the expanded hospital footprint, with the company still generating revenue in the low tens of millions annually. Management has indicated that revenue recognition will lag contract signings as hospitals integrate CT:VQ into clinical workflows and physician adoption ramps within each institution.

Competitive Positioning and Market Opportunity

CT:VQ represents a potentially disruptive alternative to nuclear medicine ventilation-perfusion scans, which have been the standard of care for assessing conditions such as pulmonary embolism and chronic lung disease. The technology’s key advantages include elimination of radioactive tracers, faster scan times, and the ability to generate functional lung maps from CT scans already being performed for anatomical assessment.

The addressable market spans more than 4,000 Medicare-certified hospitals in the United States alone, with 4DMedical’s strategy focused on establishing CT:VQ as standard of care through adoption at influential academic medical centres. The “lighthouse site” approach aims to generate clinical evidence and physician endorsements that cascade to surrounding community hospitals and regional healthcare systems.

Beyond CT:VQ, 4DMedical’s product portfolio includes XV LVAS (four-dimensional lung imaging from X-rays), CT LVAS (structural lung analysis), and IQ-UIP (machine learning for interstitial lung disease diagnosis). This multi-product platform provides diversification and cross-selling opportunities, though CT:VQ currently represents the company’s primary commercial focus in North America.

Competition in the respiratory imaging space includes traditional nuclear medicine, emerging MRI-based ventilation imaging, and AI-enhanced CT interpretation tools from established medical imaging vendors. However, 4DMedical’s first-mover advantage in CT-based ventilation-perfusion imaging and its growing clinical validation at elite institutions provide differentiation in what remains a fragmented and evolving market.

Outlook

The Mayo Clinic deployment positions 4DMedical at a critical juncture where symbolic validation must translate into material revenue growth to sustain the current valuation. Management’s near-term priorities include expanding the installed base of CT:VQ sites, driving scan volume growth at existing customers, and advancing the clinical evidence base through peer-reviewed publications and conference presentations.

The company’s partnership strategy with Philips provides a potential accelerant, particularly for penetration of government healthcare systems where Philips has established relationships. Additional regulatory milestones, such as potential transition from Category III to Category I CPT reimbursement codes, could further de-risk adoption by signalling mainstream acceptance of the technology.

Markets will be closely monitoring upcoming quarterly results for evidence that hospital contracts are converting to meaningful per-scan revenue. The lag between contract signing and revenue recognition, driven by integration timelines, physician training, and clinical workflow adoption, means that today’s announced Mayo deployment may not materially impact financial results for several quarters.

The company’s ability to sign additional top-tier academic medical centres will also be scrutinised, with each new lighthouse site reinforcing the standard-of-care narrative while contract signing pauses could trigger reassessment of the adoption trajectory. Competitive dynamics, including potential responses from established imaging vendors or alternative modalities, represent an additional variable that could influence market share assumptions.

Today’s extraordinary move reflects markets repricing 4DMedical from a speculative medical technology play to a company with credible commercial traction at the highest levels of U.S. healthcare, though the path from validation to profitability will determine whether current valuations prove prescient or premature. Either way, 4DX bulls will enjoy the day.